Logo
x

Search

Subscribe Now

rapt therapeutics

RAPT Therapeutics and Jemincare Pharmaceutical Sign an Exclusive License Agreement to Develop JYB1904 (RPT904)

RAPT Therapeutics and Jemincare Pharmaceutical Sign an Exclusive License Agreement to Develop JYB1904 (RPT904)

  • December 24, 2024
Rapt Therapeutics Reports the P-II Study Results of Tivumecirnon Plus Keytruda for Treating Head and Neck Cancer

Rapt Therapeutics Reports the P-II Study Results of Tivumecirnon Plus Keytruda for Treating Head and Neck Cancer

  • April 10, 2024
The US FDA Places Clinical Hold on the Trials Assessing RAPT Therapeutics’ Zelnecirnon

The US FDA Places Clinical Hold on the Trials Assessing RAPT Therapeutics’ Zelnecirnon

  • February 21, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.